Overview

• Sanofi has committed at least $20 billion through 2030 to enhance its U.S. manufacturing and research capabilities.
• The investment will focus on upgrading six major U.S. sites and forming partnerships with domestic manufacturers.
• The decision responds to Trump administration trade policies, including potential pharmaceutical tariffs and stricter inspections of foreign plants.
• Sanofi's U.S. operations, which employ 13,000 people, generated nearly half of its Q1 2025 global revenue.
• Other major pharmaceutical companies, including Roche, Novartis, and Eli Lilly, have announced similar large-scale U.S. investments this year.